Psoriatic Arthritis

Secukinumab Receives FDA Approval for Pediatric Patients with PsA
December 23, 2021

Secukinumab is the only biologic treatment in the US that’s approved by the FDA for pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

Study: Risk of Psoriasis Related to BMI
December 21, 2021

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.

Apremilast Use During COVID-19
December 21, 2021

A recent study investigated apremilast use for psoriasis during COVID-19 infection.

Upadacitinib Receives FDA Approval for Active Psoriatic Arthritis
December 15, 2021

The FDA approves upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active psoriatic arthritis.

Pregnancy outcomes vary in women with psoriatic arthritis
November 03, 2021

The study examines the impact of antirheumatic treatment on pregnancy outcomes in women with psoriatic arthritis.

What to Know: Phase 3 Findings on Promising Psoriasis Pipeline
October 24, 2021

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays
September 02, 2021

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

FDA Requiring Black Box Warning for Certain JAK Inhibitors
September 02, 2021

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.

FDA Delays Impacting Inflammatory Skin Disease Community
August 06, 2021

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

Brace for Breakthroughs in Psoriasis, Psoriatic Arthritis
July 30, 2021

As COVID-19 eases, the FDA is breaking through its backlog and clinical trials are moving forward, opening the way for a new wave of treatments.